Levodopa–induced dyskinesias in the absence of nigrostriatal degeneration


  • Erwan Bézard PhD,

    Corresponding author
    1. University of de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France
    2. Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France
    • Correspondence to: Dr. Erwan Bezard, CNRS UMR 5293, IMN, Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France; erwan.bezard@u-bordeaux2.fr

    Search for more papers by this author
  • C. Warren Olanow MD, FRCPC,

    1. Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA
    Search for more papers by this author
  • José A. Obeso MD, PhD

    1. Movement Disorders Group, Neurosciences Division, Center for Applied Medical Research, and Department of Neurology and Neurosurgery, University Clinic and Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), University of Navarra, Pamplona, Spain
    Search for more papers by this author

  • Funding agencies: Funding from Spanish Science and Education Ministry and European Union (REPLACES). Agence Nationale de la Recherche, MJFF, FP7 from EU, France Parkinson, Fondation de France, Cariplo Foundation.

  • Relevant conflicts of interest/financial disclosures: Dr. J.A. Obeso has served previously in the Advisory Board of GSK (UK), and received honorarium for lecturing in meetings organized by GSK (Spain), Lundbeck-TEVA and UCB. Dr. Bezard has equity stake in Motac holding Ltd and receives consultancy payments from Motac Neuroscience Ltd. Dr. C.W. Olanow received consulting fees from Novartis and Orion.

  • Full financial disclosures may be found in the Acknowledgments section online.

No abstract is available for this article.